

What is claimed is:

1. A method of producing complete Hepatitis A Virus particles comprising the steps of treating an HAV preparation from a cell culture supernatant of an HAV infected cell culture with a nucleic acid degrading agent and a protease, and isolating said purified preparation of complete HAV particles.
2. The method according to claim 1, which further comprises concentrating said cell culture supernatant prior to treating said nucleic acid degrading agent and protease.
3. The method according to claim 2, which comprises concentrating said cell culture supernatant by filtering.
4. The method of claim 1, wherein the nucleic acid degrading agent is an enzyme.
5. The method according to claim 4, wherein the enzyme is a DNase.
6. The method according to claim 1, wherein the protease is a microbial protease.
7. The method according to claim 1, wherein said protease is Pronase or an enzymatically active fraction thereof.
8. The method according to claim 1, wherein said protease is purified *Streptomyces griseus* trypsin.
9. A method according to claim 1, wherein the cell culture is a VERO cell culture.

10. The method according to claim 1, wherein said cells are grown in a serum free or serum and protein free medium.
11. The method according to claim 1, wherein said preparation of purified complete HAV particles is isolated by filtering.
12. The method according to claim 1, wherein said preparation of complete HAV particle has less than about 30 pg contaminating nucleic acid/ IU HAV antigen.
13. The method according to claim 1, wherein said preparation of complete HAV particle has at least about 5000 IU of HAV antigen / mg protein.
14. The method according to claim 1, further comprising a step of treating the preparation of complete HAV particle with a virus inactivating agent.
15. A method of production of a purified Hepatitis A Virus preparation comprising the steps of treating the HAV preparation from the supernatant of an HAV infected cell culture with a nucleic acid degrading agent and a protease, isolating said purified preparation of complete HAV particles and isolating purified mature HAV virions from said preparation complete HAV particle.
16. The method according to claim 15, which comprises concentrating said cell culture supernatant prior to treating said nucleic acid degrading agent and protease.
17. The method according to claim 16, which comprises concentrating said cell culture supernatant by filtering.

18. The method of claim 15, wherein the nucleic acid degrading agent is an enzyme.

19. The method according to claim 15, wherein the protease is a microbial protease.

20. A method according to claim 15, wherein the cell culture is a VERO cell culture.

21. The method according to claim 15, wherein said cells are grown in a serum free or serum and protein free medium.

22. The method according to claim 15, wherein said preparation is substantially free of contaminating proteins from the cells or the cell culture medium.

23. The method according to claim 15, wherein said preparation has less than about 0.5 pg contaminating nucleic acid /IU HAV antigen.

24. The method according to claim 15, comprising a step of treating the purified HAV particles with a virus inactivating agent.

25. The method according to claim 24, wherein treating of purified HAV particles with a virus inactivating agent is performed prior to isolation of mature HAV virions.

26. A method of production of a purified complete HAV particle preparation consisting which consists of purifying complete HAV particles from a cell culture supernatant an HAV infected cells by filtering.

27. The method according to claim 26, comprising further treating said preparation with a virus inactivating agent.
28. A method of production of a purified mature HAV particle preparation which consists of purifying mature HAV particles from a cell culture supernatant of HAV infected cells by filtering and centrifugation.
29. The method according to claim 28 which comprises further treating with a virus inactivating agent.
30. A method of isolating complete HAV particle from a cell-free cell culture supernatant of HAV infected cells comprising the steps of treating the HAV preparation from the supernatant of an HAV infected cell culture with a nucleic acid degrading agent and a protease, and isolating said purified preparation of complete HAV particles.
31. The method according to claim 30, wherein the preparation is free of HAV precursor polypeptide.
32. A method of isolating mature HAV particle from a cell culture supernatant HAV harvest of HAV infected cells comprising the steps of treating the HAV preparation from the supernatant of an HAV infected cell culture with a nucleic acid degrading agent and a protease, isolating said purified preparation of complete HAV, and isolating from said preparation of complete HAV particle a preparation consisting of mature HAV particle.
33. A preparation of complete HAV particle free of HAV precursor polypeptide and contaminating cell or cell culture protein.

34. The preparation according to claim 33, wherein said preparation has less than about 30 pg contaminating nucleic acid / IU HAV antigen.

35. The preparation according to claim 34, wherein said preparation has at least about 5000 IU of HAV antigen / mg protein.

36. The preparation according to claim 33, consisting of inactivated, purified complete HAV particles.

37. A preparation of purified mature HAV particle free of HAV precursor polypeptide and contaminating cell or cell culture protein.

38. The preparation according to claim 37, which is free of HAV provirions.

39. The preparation according to claim 37, wherein said preparation has less than about 0.5 pg contaminating nucleic acid from the cells or the cell culture / IU of HAV antigen.

40. The preparation according to claim 38, consisting of inactivated, purified mature HAV particles.

41. A method for production of HAV vaccine comprising the steps of treating an HAV preparation from the cell culture supernatant of an HAV infected cell culture with a nucleic acid degrading agent and a protease, and isolating said purified preparation of complete HAV particles, and preparing an immunogenic composition comprising a preparation consisting of purified, complete HAV virions.

42. A method for the production of an HAV vaccine comprising the steps of treating the HAV preparation from the supernatant of an HAV infected cell culture

with a nucleic acid degrading agent and a protease, isolating said purified preparation of complete HAV particles and isolating purified mature HAV virions from said preparation complete HAV particle, and preparing an immunogenic composition comprising a preparation consisting of purified, mature HAV virions.

43. The method according to claim 42, wherein the vaccine is substantially free of contaminating proteins from the cell culture.

44. A method for production of an inactivated HAV vaccine comprising the steps of treating the HAV preparation from the supernatant of an HAV infected cell culture with a nucleic acid degrading agent and a protease, isolating said purified preparation of complete HAV particles and isolating purified mature HAV virions from said preparation complete HAV particle, and preparing an immunogenic composition comprising a preparation, wherein the HAV preparation is treated with an inactivation agent prior or after isolating of mature HAV virion particle.

45. AN HAV vaccine comprising an host protective amount of a mature HAV particle preparation according to claim 37.

46. A vaccine according to claim 45, wherein said preparation is free of HAV precursor polypeptide and HAV provirions.

47. The vaccine according to claim 45, wherein said host protective dose is less than about 25 IU of HAV antigen / dose:

48. The vaccine according to claim 45, wherein said host protective dose is between about 10 and about 25 IU of HAV antigen / dose.

49. The vaccine according to claim 45, comprising an immune stimulating agent.

50. The vaccine according to claim 45, further comprising Hepatitis B virus antigen.

51. The vaccine according to claim 45, further comprising an antigen from a viral or bacterial pathogen.

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000